Structure-Guided Cyclic Peptide Design: Toward Next-Generation Immune Checkpoint Inhibitors

Immune checkpoint inhibitors targeting PD-1/PD-L1 have changed cancer treatment. But monoclonal antibodies come with clear drawbacks: high costs, limited tumor penetration, and immune-related side effects. That has pushed researchers to look for other molecular formats. Cyclic peptides stand out—they are stable, bind with precision, and penetrate tissues well. This article looks at a recent study that designed a cyclic peptide to block PD-1/PD-L1, walking through the workflow from hotspot mapping to in vivo validation. It also explores how screening and design platforms can help move these molecules from discovery toward real-world use.

Immune Checkpoint Blockade: Where Success Meets Unmet Needs

Antibody-based immune checkpoint inhibitors have made real progress in solid tumors, but the approach is hitting its limits. PD-1/PD-L1 has a flat, shallow interface—no deep pocket for small molecules to grab onto. Antibodies bind well enough, but their size keeps them from penetrating tumors effectively.

Monoclonal Antibody Limitations: The Push for Alternative Modalities

Monoclonal antibodies targeting PD-1/PD-L1 have demonstrated significant efficacy in advanced malignancies including melanoma, non-small cell lung cancer, and various other solid tumors. However, high manufacturing costs, potential immunogenicity, and limited solid tumor penetration restrict their broader application. Additionally, only a subset of patients responds to current antibody therapies, and immune-related adverse events can lead to severe toxicities. These unmet clinical needs have driven researchers to explore alternative molecular formats that are structurally more compact, less costly, and offer superior tissue distribution.

Cyclic Peptides as a Rational Alternative

Cyclic peptides occupy a molecular weight range (typically 1–2 kDa) that bridges small molecules and antibodies, combining advantages from both classes. Their cyclic backbone confers superior proteolytic stability and conformational pre-organization compared to linear peptides, enabling effective mimicry of key binding motifs at protein-protein interaction interfaces, while also offering better tissue penetration than antibodies. The literature indicates that through structure-guided design, cyclic peptides can precisely target flat, difficult-to-drug interfaces such as PD-1/PD-L1, opening new avenues for immune checkpoint blockade.

Deconstructing the Design Strategy: From Hotspot Identification to Functional Validation

The core value of the featured study lies in its complete presentation of a closed-loop design workflow, from structural analysis to in vivo validation. By systematically deconstructing this workflow, we can clearly see that successful cyclic peptide drugs do not emerge by chance, but rather stem from deep understanding of the binding interface, appropriate application of computational tools, and multi-dimensional experimental validation.

Mapping the Binding Interface: Hotspot Residues as the Design Blueprint

The researchers first analyzed the PD-1/PD-L1 interaction interface via molecular docking, confirming it as a flat, hydrophobic surface with a contact area of 1970 Ų. Key hotspot residues were identified—Ile134, Glu136, Thr76 on PD-1, and Tyr123, Arg125, Asp26 on PD-L1—forming a complex network of hydrogen bonds, salt bridges, and hydrophobic interactions. Notably, these hotspot residues overlapped extensively with the binding sites of approved antibodies and reported linear peptide inhibitors, validating their reliability as a design starting point.

Visualization of the interaction between PD-1 and a variety of bioactive molecules^1,4

From Linear Mimetics to Cyclic Candidates: Structure-Based Optimization

Based on key fragments of PD-L1 involved in PD-1 binding, the researchers designed five mimetic peptides, which were further optimized into 22 cyclic peptide candidates. Through HPEPDOCK molecular docking screening, combined with metrics such as hydrogen bond count and docking scores, PD-1-0514, PD-1-0518, PD-1-0519, and PD-1-0520 were prioritized. Among these, PD-1-0520 demonstrated the strongest binding potential with a docking score of –287.79 and 11 hydrogen bonds. In its sequence G-A-D-Y-K-G, tyrosine (Y) forms π-π stacking with Ile134 of PD-1, while aspartic acid (D) and lysine (K) engage in electrostatic interactions with Glu136 and Gln75, respectively—a design that precisely leverages the chemical properties of the hotspot residues.

Molecular docking investigation of the interaction between designed peptides and the human PD-1 protein using the HPEPDOCK server^2,4

Molecular Dynamics: Validating Binding Stability and Free Energy

Five-microsecond all-atom molecular dynamics simulations further confirmed the structural stability of the cyclic peptide/PD-1 complexes. Binding free energies calculated via MM/PBSA showed that PD-1-0520 achieved a ΔGbinding of –167.4 kJ/mol, significantly outperforming other candidates and the native PD-1/PD-L1 complex (–90.05 kJ/mol). The binding free energy was primarily driven by van der Waals interactions, indicating that the cyclic peptide formed a tight and stable hydrophobic contact network with PD-1. These computational predictions provided strong confidence for subsequent in vitro experiments.

Dynamic simulation results^3,4

From Bench to Bedside: In Vitro and In Vivo Efficacy

In vitro pull-down assays confirmed that PD-1-0520 reduced PD-1/PD-L1 binding to approximately 20% of control levels at 10 µM concentration. In A375 and HCT116 cells, the cyclic peptide exhibited IC50 values of 17.3 µM and 14.3 µM, respectively, and significantly enhanced T-cell-mediated tumor cell killing in co-culture systems with Jurkat T cells. In the B16-F10 melanoma model in vivo, PD-1-0520 achieved a 68% tumor inhibition rate at a dose of 10 mg/kg, with no observed body weight loss or systemic toxicity. Immunohistochemistry and immunofluorescence analyses revealed significantly increased CD8+ T-cell infiltration in tumor tissues from treated groups, along with upregulated GZMB and IFN-γ expression, confirming the transition of the immune microenvironment from cold to hot.

Translating Cyclic Peptide Discovery into Tangible Programs

The complete workflow presented in the featured study—from structural design to in vivo validation—precisely reveals the critical success factors in cyclic peptide drug development. For any research team aiming to advance similar innovative concepts toward clinical candidates, these factors represent both technical challenges and efficiency bottlenecks.

Key Challenges in Cyclic Peptide Drug Discovery

Through analysis of the literature, several core challenges commonly encountered in cyclic peptide drug development can be summarized:

• Precise design of screening conditions: Protein-protein interaction interfaces are often highly sensitive to screening conditions. Parameters such as buffer composition, immobilization methods, and wash stringency directly determine whether enrichment results genuinely reflect target binding.
• Cyclization strategy and conformational control: The choice of ring size, cyclization site, and cyclization method—head-to-tail, side-chain, disulfide bridging—directly impacts conformational rigidity and the entropic penalty of binding.
• Balancing stability and developability: High-affinity cyclic peptides may carry liabilities in serum stability, cell permeability, or synthetic scalability that require systematic evaluation early in the program.
• Multi-parameter optimization efficiency: From hotspot residue identification to lead optimization, an efficient design-synthesize-test-analyze cycle is essential for rapidly establishing structure-activity relationships.

Creative Peptides' Empowering Strategy: Integrating Screening and Design Capabilities

Addressing the challenges above requires more than single-technology platforms. An end-to-end solution that integrates diverse library construction, orthogonal validation capabilities, and structure-guided design support is essential for accelerating cyclic peptide discovery programs. Our Cyclic Peptide Screening and Design Platforms are purpose-built to meet these needs.

Creative Peptides' Integrated Capabilities: From Screening to Design for Immune Checkpoint Programs

We provide comprehensive cyclic peptide drug discovery support for research teams working on immune checkpoints and other challenging targets. Whether in early hit screening or lead optimization phases, our platforms can be flexibly configured according to project goals, target biology, and downstream development requirements.

Let's Move Your Program Forward!

Creative Peptides help research teams turn challenging targets into cyclic peptide leads. Whether you are starting from a binding interface, a known peptide motif, or a clean slate, our screening and design platforms are built to get you from hit identification to candidate-quality material with fewer detours.

• Screening that delivers actionable hits, not just long sequence lists
• Design support that links structure to SAR from the first scaffold
• Stability and developability checks built into the optimization process
• Seamless handoffs from design to synthesis to validation

Ready to discuss your project? Explore our Cyclic Peptide Screening Services and Cyclic Peptide Design Services online, or send us your target details—we will get back to you with a path forward.